- Home
- FAX vs PACB Comparison
FAX vs PACB Comparison
Compare FAX & PACB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FAX | PACB |
|---|---|---|
| Founded | 1986 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 625.8M | 555.5M |
| IPO Year | N/A | 2010 |
Fundamental Metrics
Financial Performance| Metric | FAX | PACB |
|---|---|---|
| Price | $15.53 | $2.57 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $2.08 |
| AVG Volume (30 Days) | 833.6K | ★ 8.1M |
| Earning Date | 01-01-0001 | 02-12-2026 |
| Dividend Yield | ★ 12.09% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $154,584,000.00 |
| Revenue This Year | N/A | $4.19 |
| Revenue Next Year | N/A | $12.04 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.33 | $0.85 |
| 52 Week High | $2.84 | $2.73 |
Technical Indicators
Market Signals| Indicator | FAX | PACB |
|---|---|---|
| Relative Strength Index (RSI) | 56.52 | 63.61 |
| Support Level | $15.25 | $2.09 |
| Resistance Level | $15.54 | $2.73 |
| Average True Range (ATR) | 0.15 | 0.20 |
| MACD | 0.02 | 0.05 |
| Stochastic Oscillator | 73.60 | 82.25 |
Price Performance
Historical ComparisonAbout FAX abrdn Asia-Pacific Income Fund Inc.
Aberdeen Asia-pacific Income Fund Inc is a United States-based closed-end, non-diversified management investment company. Its principal investment objective is to seek current income along with capital appreciation. The fund invests in Asian debt securities, Australian debt securities, European debt securities and others.
About PACB Pacific Biosciences of California Inc.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.